Could fewer shots prevent rabies? new trial tests simpler vaccine schedules

NCT ID NCT07275645

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 3 trial is testing whether simpler vaccination schedules for rabies are as effective as the standard 5-dose regimen. About 3,000 healthy people aged 10 to 60 will receive the vaccine in different patterns, including fewer total doses. Researchers will measure immune responses and track side effects to find the best balance of protection and convenience.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Rabies vaccine (human diploid cell), freeze-dried
What this could lead to
If successful, this could lead to simpler, fewer-dose vaccination schedules for rabies, making prevention easier and more accessible.
What could go wrong
This is a phase 3 trial, but it compares different schedules of an already approved vaccine type. The main risk is that simplified schedules may not be as effective as the standard one.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RABIES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Gucheng county Center for Disease control and Prevention

    Xiangyang, Hubei, China

  • Qichun County Center for Disease Control and Prevention

    Huanggang, Hubei, China

  • Xiangzhou District Center for Disease Control and Prevention

    Xiangyang, Hubei, China

  • Yunyang District Center for Disease Control and Prevention

    Shiyan, Hubei, China

  • Zhushan county Center for Disease control and Prevention

    Shiyan, Hubei, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.